Details for Patent: 8,388,941

« Back to Dashboard

Which drugs does patent 8,388,941 protect, and when does it expire?

Patent 8,388,941 protects TRAVATAN Z and is included in one NDA. There has been one Paragraph IV challenge on Travatan Z.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 8,388,941

Title:	Self preserved aqueous pharmaceutical compositions
Abstract:	The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being `self-preserved`. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.
Inventor(s):	Chowhan; Masood A. (Arlington, TX), Keith; David J. (Washington, MO)
Assignee:	Alcon Research, Ltd. (Fort Worth, TX)
Application Number:	12/441,995
Patent Claim Types: see list of patent claims	Composition; Use;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product
Novartis Pharms Corp	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes	► Subscribe	► Subscribe	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,388,941

PCT Information
PCT Filed	September 20, 2007	PCT Application Number:	PCT/US2007/079094
PCT Publication Date:	April 10, 2008	PCT Publication Number:	WO2008/042619

International Patent Family for Patent: 8,388,941

Country	Document Number	Estimated Expiration
Australia	2007304996	► Subscribe
Brazil	PI0717093	► Subscribe
Canada	2663817	► Subscribe
China	101522171	► Subscribe
European Patent Office	2066300	► Subscribe
Spain	2543349	► Subscribe
Hong Kong	1126419	► Subscribe
Japan	2010504990	► Subscribe
Japan	2013234199	► Subscribe
Japan	5394927	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview